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Introduction
Chronic myelogenous leukemia (CML) is the commonest 
myeloproliferative neoplasm encountered and it is charac-
terized by the hallmark translocation t(9;22) or BCR-ABL1 
transcripts. The natural history of the disease has three 
phases: the chronic phase (CP) followed by progressive 
transformation to the accelerated or blast phase. The 
defining criteria for the blast phase are the presence of 
at least 20% blasts in peripheral blood or bone marrow or 
extramedullary proliferation of blasts [1]. Infiltration of the 
central nervous system as the sole site of extramedullary 
blast crisis is exceptional and deserves attention.
Clinical vignette
We report the case of a 42-year-old male who was diagno-
sed as a case of chronic myelogenous leukemia in chronic 
phase (CML-CP) in August 2016. At the time of diagnosis, 
hemoglobin (Hb) was 11.2 g/dL, platelet counts were nor-
mal, and white blood cell counts were 120 × 103/mL with 
left shift, 7% basophils, and 5% blasts. Bone marrow cyto-
genetics confirmed the presence of BCR-ABL1 transcript 
in all metaphases. Clinically, the patient had splenome-
galy 3 cm below the left costal margin. He was started on 
imatinib therapy. He responded well to therapy achieving 
major molecular response (MMR) at the end of 1 year 
(BCR-ABL1 by reverse-transcriptase polymerase chain 
reaction [RT-PCR] = 0.015%). However, in November 2018 
he presented with severe frontal headache and vomiting. 
Magnetic resonance imaging (MRI) brain revealed chronic 
small vessel ischemia and nonspecific demyelination. Bone 
marrow studies showed a normocellular bone marrow. Flow 
cytometry of cerebrospinal fluid (CSF) was suggestive of 
pre-B cell lymphoblasts. He was thus diagnosed as CML 
in central nervous system (CNS) blast crisis and managed 
with triple intrathecal chemotherapy, which included 
methotrexate (12 mg), cytosine arabinoside (30 mg), and 
dexamethasone (4 mg), a total of four doses in a month 
along with cranial radiotherapy. The patient responded 
well to the treatment without residual sequelae and was 
started on the second-generation tyrosine kinase inhibitor 
(TKI), tablet dasatinib 70 mg twice a day and was being 
worked up for bone marrow transplantation After 2 months, 
he again presented with CNS relapse and complained of 
acute onset ptosis and diplopia in the absence of fever, 
headache, seizure, or any trauma. Ophthalmologic exami-
nation revealed cranial nerve III palsy with pupillary sparing. 
Haematological parameters were Hb 10.0 g/dL, TLC 3,200/ 
/mL, and platelet count 177 × 103/mL. Bone marrow study 
revealed cellular reactive marrow without an increase in 
blasts. MRI brain showed nonspecific white matter changes. 
The CSF study showed markedly elevated white blood cell 
(WBC) count of 270/mL with 90% blasts (Figure 1); the 
total protein was 56 mg/dL with raised globulins, glucose 
was 55 mg/dL, and adenosine deaminase and lactate 
dehydrogenase levels were normal. CSF flow cytometry 
this time again was consistent with pre-B lymphoblasts 
(positive for CD10, CD19, CD79a, HLA-DR and negative for 
CD13, CD33, CD117, cyto MPO). He was again started on 
triple intrathecal chemotherapy and cranial radiotherapy. 
However, he had progressive deterioration in his neurolo-
gical status and succumbed to his illness after two cycles 
of chemotherapy. Postmortem could not be performed due 
to unwillingness by family members.
Discussion
Extramedullary blast crisis in CML is rare and CNS invol-
vement is a rarity that is noted in only 5–10% of patients 
[2]. Our patient had two episodes of isolated CNS blast 
crisis, despite having achieved haematologic and molecular 
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remission. The most plausible explanation for extramedul-
lary relapse is the poor penetration of imatinib through the 
blood–brain barrier, hence CNS serves as the sanctuary 
site leading to relapses. Second-generation TKIs such as 
dasatinib, nilotinib, and bosutinib are more effective in 
treating CNS disease due to better penetration through the 
blood–brain barrier [3]. Unfortunately, our patient relapsed 
even with dasatinib treatment. Rare case reports of isolated 
CNS relapse with dasatinib therapy like our patient have 
been reported [4, 5].
Systemic chemotherapy, which includes daily cytara-
bine 200 mg/m2 and daunorubicin 40 mg/m2 have been 
used for treatment in CML blast crisis. So far, allogeneic 
hematopoietic stem-cell transplantation is still the only way 
to cure CML and is one of the first treatment options for 
children with chronic myelogenous leukemia [6].
Despite advances in molecular disease detection and 
monitoring, there is still a need to identify the risk factors 
leading to CNS relapses. Unfortunately, CSF study is not 
included in the CML diagnostic workup or monitoring pro-
tocols, unlike other acute leukemias and lymphomas.
Through this case, we intend to highlight the fact and 
also caution physicians that one should be aware of the 
possibility of CNS relapse in CML patients on imatinib even 
if they have achieved haematological and cytogenetic re-
mission. Hence, a high index of suspicion, prompt CSF 
studies, and aggressive management are key to salvaging 
CML patients.
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Figure 1. LG stained cytospin smears of cerebrospinal fluid. Markedly cellular smears showing atypical mitosis, numerous blasts which have 
high N:C ratio, a large nucleus with open chromatin, and prominent nucleoli 400 ×
